References
- Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14(3):485–496.
- Villasenor-Park J, Wheeler D, Grandinetti L. Psoriasis: evolving treatment for a complex disease. Cleve Clin J Med. 2012;79(6):413–423.
- Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
- Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26(3):235–239.
- Mahil SK, Capon F, Barker JN. Genetics of psoriasis. Dermatol Clin. 2015;33(1):1–11.
- Sharma J, Balakrishnan L, Datta KK, et al. A knowledgebase resource for interleukin-17 family mediated signaling. J Cell Commun Signal. 2015 Sep; 9(3):291–296.
- Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174–181.
- Chandrakumar SF, Yeung J. Interleukin-17 antagonists in the treatment of psoriasis. J Cutan Med Surg. 2015;19(2):109–114.
- Grine L, Dejager L, Libert C, et al. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev. 2015;26(1):25–33.
- Mashiko S, Bouguermouh S, Rubio M, et al. Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J Allergy Clin Immunol. 2015;136(2):351–9e1.
- Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–729.
- Malakouti M, Brown GE, Wang E, et al. The role of IL-17 in psoriasis. J Dermatolog Treat. 2015;26(1):41–44.
- Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9(6):650–657.
- Stockinger B, Veldhoen M, Martin B. Th17 T cells: linking innate and adaptive immunity. Semin Immunol. 2007;19(6):353–361.
- Isailovic N, Daigo K, Mantovani A, et al. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1–11.
- Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092–1102.
- Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203(10):2271–2279.
- Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–852.
- Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1):490–500.
- Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10(7):479–489.
- Villanova F, Flutter B, Tosi I, et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol. 2014;134(4):984–991.
- Pantelyushin S, Haak S, Ingold B, et al. RORgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J Clin Invest. 2012;122(6):2252–2256.
- Skepner J, Ramesh R, Trocha M, et al. Pharmacologic inhibition of RORgammat regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. J Immunol. 2014;192(6):2564–2575.
- Takatori H, Kanno Y, Watford WT, et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med. 2009;206(1):35–41.
- Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677–687.
- Chiricozzi A, Nograles KE, Johnson-Huang LM, et al. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS One. 2014;9(2):e90284.
- Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122(2):201–206.
- Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273–290.
- Rizzo HL, Kagami S, Phillips KG, et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186(3):1495–1502.
- Valeant announces FDA acceptance of BLA submission for brodalumab in moderate-to-severe plaque psoriasis [press release]. Quebac, Canada: PRNewswire; 2016. 25 Jan, 2016.
- Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
- Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
- Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
- Lee E, Zarei M, LaSenna C, et al. Psoriasis targeted therapy: characterization of interleukin 17A expression in subtypes of psoriasis. J Drugs Dermatol. 2015;14(10):1133–1136.
- Mansikka HRM, Hugunin M, Ivanov A, et al. Safety, tolerability, and functional activity of ABT-122, a dual TNF- and IL-17A-targeted DVD-Ig™, following single-dose administration in healthy subjects. American College of Rheumatology 2014 Annual Meeting; 2014 November 14-19; Boston, MA.
- A phase 2 study to investigate the safety, tolerability and efficacy of ABT-122 in subjects with active psoriatic arthritis who have an inadequate response to methotrexate (NCT02349451). [ cited 2016 Mar 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT02349451
- Phase 2, multicenter, open-label extension (OLE) study with ABT-122 in rheumatoid arthritis subjects who have completed the preceding M12-963 study (NCT02433340). [ cited 2016 Mar 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT02433340
- First-in-human study to evaluate safety, tolerability, and pharmacokinetics of BCD-085 in healthy subjects (NCT02380287). [ cited 2016 Mar 11]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02380287
- UCB R&D pipeline. [ cited 2016 Mar 26]. Available from: http://www.ucb.com/rd/pipeline/development
- A study to assess the safety, pharmacokinetics and pharmacodynamics of UCB4940 in patients with psoriasis (NCT02529956). [ cited 2016 Mar 28]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02529956
- Multiple dose study of UCB4940 in subjects with psoriatic arthritis (NCT02141763). [ cited 2016 Mar 28]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02141763
- UCB’s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis [press release]. Brussels (Belgium). 2016 Jun 10.
- Multiple dose study of UCB4940 as add-on to certolizumab pegol in subjects with rheumatoid arthritis (NCT02430909). [ cited 2016 Mar 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02430909
- Novartis pipeline 2015 annual report. [ cited 2016 Mar 17]. Available from: https://www.novartis.com/sites/novartisemea.prod.acquia-sites.com/files/novartis-pipeline-2015-annual-report.pdf
- Single and multiple dose escalation study to assess the safety and tolerability of CJM112 in psoriasis. (NCT01828086). [ cited 2016 Mar 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01828086
- Wiendl H, Dahlke F, Bennett D, et al.; IL-17 neutralization by subcutaneous CJM122, a fully human anti-IL-17A monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis: study design of a phase 2 trial. 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2015 Oct 7–10; Barcelona, Spain.
- Efficacy, safety, and pharmacokinetics study of CJM112 in hidradenitis suppurativa patients (NCT02421172) [ cited 2016 Mar 17]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02421172
- An efficacy and safety study of CNTO 6785 in participants with active rheumatoid arthritis despite methotrexate therapy. (NCT01909427). [ cited 2016 Mar 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01909427
- A study to evaluate the effectiveness and safety of CNTO6785 in patients with moderate to severe chronic obstructive pulmonary disease. (NCT01966549). [ cited 2016 Mar 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01966549
- Safety and tolerability of COVA322 in patients with stable chronic moderate-to-severe plaque psoriasis. (NCT02243787). [ cited 2016 Mar 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT02243787
- Silacci M, Lembke W, Woods R, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. Mabs. 2016;8(1):141–149.
- Covagen pipeline. [ cited 2016 Mar 11]. Available from: http://covagen.com/pipeline/cova322/
- Safety study to evaluate LY3114062 in participants with inflammatory arthritis. (NCT02144272). [ cited 2016 Mar 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02144272
- Eli Lilly clinical development pipeline. [ cited 2016 Mar 18]. Available from: https://www.lilly.com/_Assets/SiteCollectionDocuments/Pipeline/Clinical-Development-Pipeline/index.html
- Allan B, Benschop R, Lu J, inventorAnti-baff-anti-il-17 bispecific antibodies. USA; 2013.
- Vanheusden K, Detalle L, Hemeryck A, et al. Pre-clinical proof-of-concept of ALX-0761, a nanobody (R) neutralizing both IL-17A and F in a cynomolgus monkey collage induced arthritis model. Annual Meeting of the American College of Rheumatology; 2013 Oct 30; San Diego, CA.
- Multiple ascending dose trial of MSB0010841 (Anti-IL17A/F nanobody) in psoriasis subjects. (NCT02156466). [ cited 2016 Mar 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT02156466
- Rohn TA, Jennings GT, Hernandez M, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol. 2006;36(11):2857–2867.
- Dallenbach K, Maurer P, Rohn T, et al. Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease. Eur J Immunol. 2015;45(4):1238–1247.
- Domainex announces that compounds from its IKKepsilon programme have activity against the IL-17 signaling pathway [press release]. Cambridge (UK); 2012.
- Domainex announces the grant of US and European patents for its lead programme, targeting IKK epsilong and TBK1 for the treatment of diseases such as COPD and psoriasis [press release]. Cambridge (UK); 2015 May 11.
- Domainex, Novel treatment for inflammatory diseases [ cited 2016 Mar 28]. Available from: http://www.domainex.co.uk/drug-discovery-pipeline/inflammatory-diseases
- Hirahara K, Ghoreschi K, Laurence A, et al. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev. 2010;21(6):425–434.
- Lin H, Song P, Zhao Y, et al. Targeting Th17 cells with small molecules and small interference RNA. Mediators Inflamm. 2015;2015:290657.
- Xiao S, Yosef N, Yang J, et al. Small-molecule RORgammat antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity. 2014;40(4):477–489.
- Huh JR, Leung MW, Huang P, et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature. 2011;472(7344):486–490.
- Smith SH, Peredo CE, Takeda Y, et al. Development of a topical treatment for psoriasis targeting RORgamma: from bench to skin. PLoS One. 2016;11(2):e0147979.
- Study of safety and efficacy of topical GSK3981278 ointment in plaque psoriasis. (NCT02548052). [ cited 2016 Apr 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02548052
- GSK product development pipeline March 2016. [ cited 2016 Apr 4]. Available from: https://gsk.com/media/1017505/product-pipeline-march-2016.pdf
- Huang W, Wang H, Johnson RL, et al. Identification of potent and selective RORgamma antagonists. Bethesda (MD): National Center for Biotechnology Information; 2010. (Probe Reports from the NIH Molecular Libraries Program).
- Skepner J, Trocha M, Ramesh R, et al. In vivo regulation of gene expression and T helper type 17 differentiation by RORgamma t inverse agonists. Immunology. 2015;145(3):347–356.
- Xu T, Wang X, Zhong B, et al. Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein. J Biol Chem. 2011;286(26):22707–22710.
- Baek SY, Lee J, Lee DG, et al. Ursolic acid ameliorates autoimmune arthritis via suppression of Th17 and B cell differentiation. Acta Pharmacol Sin. 2014;35(9):1177–1187.
- Vitae Pharmaceuticals pipeline overview: autoimmune diseases. [ cited 2016 Apr 5]. Available from: http://vitaepharma.com/pipeline/autoimmune-diseases/
- Vitae Pharmaceuticals achieves proof-of-concept with first-in-class RORyt inhibitor in moderate to severe psoriasis [press release]. Fort Washington (PA): Globe Newswire; 2016 Mar 16.
- An ascending multiple dose study with VTP-43742 in healthy volunteers and psoriatic patients. (NCT02555709). [ cited 2016 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02555709